SIGA Technologies Inc
NASDAQ:SIGA

Watchlist Manager
SIGA Technologies Inc Logo
SIGA Technologies Inc
NASDAQ:SIGA
Watchlist
Price: 6.28 USD -0.16%
Market Cap: 448.2m USD
Have any thoughts about
SIGA Technologies Inc?
Write Note

SIGA Technologies Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SIGA Technologies Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
SIGA Technologies Inc
NASDAQ:SIGA
Additional Paid In Capital
$238m
CAGR 3-Years
2%
CAGR 5-Years
1%
CAGR 10-Years
3%
Johnson & Johnson
NYSE:JNJ
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Additional Paid In Capital
$45.9B
CAGR 3-Years
1%
CAGR 5-Years
83%
CAGR 10-Years
41%
Pfizer Inc
NYSE:PFE
Additional Paid In Capital
$93.2B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Additional Paid In Capital
$44.5B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
1%
Eli Lilly and Co
NYSE:LLY
Additional Paid In Capital
$7.3B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
3%
No Stocks Found

SIGA Technologies Inc
Glance View

Market Cap
448.2m USD
Industry
Pharmaceuticals

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The Company’s lead product, TPOXX (oral TPOXX), is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The firm does not have a manufacturing infrastructure and does not intend to develop one for the manufacture of TPOXX. The company uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company’s CMOs apply methods and controls in facilities, which are uses for manufacturing, processing, packaging, testing, analyzing and holding pharmaceuticals, which conform to current good manufacturing practices (cGMP), the standard set by the FDA for manufacture and storage of pharmaceuticals intended for human use. For the manufacture of oral TPOXX, the Company uses the four CMOs, namely W.R. Grace and Company; Powdersize, LLC; Catalent Pharma Solutions LLC, and Packaging Coordinators, LLC.

SIGA Intrinsic Value
13.67 USD
Undervaluation 54%
Intrinsic Value
Price

See Also

What is SIGA Technologies Inc's Additional Paid In Capital?
Additional Paid In Capital
238m USD

Based on the financial report for Sep 30, 2024, SIGA Technologies Inc's Additional Paid In Capital amounts to 238m USD.

What is SIGA Technologies Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
3%

Over the last year, the Additional Paid In Capital growth was 1%. The average annual Additional Paid In Capital growth rates for SIGA Technologies Inc have been 2% over the past three years , 1% over the past five years , and 3% over the past ten years .

Back to Top